Dr Reddy’s Laboratories launches Fulvestrant Injection in US
Fulvestrant is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer
Dr Reddy’s Laboratories announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL), approved by the US Food and Drug Administration (USFDA).
The Faslodex brand and generic market had US sales of approximately $407 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Dr Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe is available in a carton containing two 5 mL single-dose prefilled syringes.
Fulvestrant is an estrogen receptor antagonist. It is indicated for the treatment of HR-positive advanced breast cancer in post-menopausal women with disease progression following endocrine therapy and HR-positive, HER-negative advanced or metastatic breast cancer in combination with palbociclib or ademaciclib in women with disease progression following endocrine therapy.
Faslodex is a trademark of the AstraZeneca group of companies.
- Advertisement -